Alnylam Pharmaceuticals (ALNY) Total Debt (2016 - 2025)

Alnylam Pharmaceuticals has reported Total Debt for 8 years, with the latest figure at $121.3 million in Q3 2025.

• For the quarter ending Q3 2025, Total Debt changed N/A year-over-year to $121.3 million; the trailing twelve-month figure through Sep 2025 stood at $121.3 million (changed N/A YoY), and the FY2024 full-year result was $93.8 million, changed N/A from the prior year.
• Total Debt for Q3 2025 stood at $121.3 million, roughly flat from $120.8 million in the prior quarter.
• The five-year high for Total Debt was $675.7 million in Q4 2021, with the low at $93.8 million in Q4 2024.
• Historically, Total Debt has averaged $225.9 million across 3 years, with a median of $120.8 million in 2025.
• The largest YoY upside for Total Debt was 253.25% in 2021 against a maximum downside of 253.25% in 2021.
• Alnylam Pharmaceuticals' Total Debt stood at $675.7 million in 2021, then sank by 86.12% to $93.8 million in 2024, then gained by 29.32% to $121.3 million in 2025.
• The last three Total Debt figures came in at $121.3 million (Q3 2025), $120.8 million (Q2 2025), and $118.1 million (Q1 2025), per Business Quant data.